Innovative new medicine R&D company treating degenerative brain diseases and central nervous system diseases
KDS2010 (SeReMABI) is a reversible inhibitor derived from a new treatment mechanism for Alzheimer's, and we're developing a new drug based on the mechanism of KDS2010 that improves cognitive function by acting on reactive astrocytes.